Beijing Centergate Technologies (holding) Co., Ltd. (SHE:000931)

Market Cap	3.83B +11.6%
Revenue (ttm)	2.48B -1.7%
Net Income	51.45M -12.5%
EPS	0.07 -12.6%
Shares Out	753.13M
PE Ratio	74.36
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	10,170,840
Average Volume	11,558,240
Open	5.16
Previous Close	5.16
Day's Range	5.08 - 5.18
52-Week Range	3.92 - 5.86
Beta	0.65
RSI	44.53
Earnings Date	Apr 18, 2026

About SHE:000931

Beijing Centergate Technologies (holding) Co., Ltd. engages in the pharmaceutical industry in China and internationally. The company offers Anemarrhena saponin BII and capsules for vascular dementia treatment; Bifonazole API, an opioid receptor antagonist; Naloxone Hydrochloride injection to relieve acute ethanol poisoning; Naltrexone Hydrochloride tablets to block the pharmacological effects of exogenous opioids; Hydrocodone acetaminophen tablets for the treatment of moderate to severe pain; Ambroxol Hydrochloride injection for acute and chron...

• Industry: Medical Instruments & Supplies
• Sector: Healthcare
• Founded: 1999
• Employees: 2,267
• Stock Exchange: Shenzhen Stock Exchange
• Ticker Symbol: 000931

Financial Performance

In 2024, SHE:000931's revenue was 2.53 billion, an increase of 11.22% compared to the previous year's 2.28 billion. Earnings were 53.59 million, an increase of 10.33%.